In a significant development, Dollvet Biyoteknoloji A.Ş., a Turkish veterinary vaccine manufacturer, has officially entered the AgResults Foot and Mouth Disease Vaccine Challenge Project in Eastern Africa. This project, managed by the Global Alliance for Livestock Veterinary Medicines (GALVmed), aims to support the development and uptake of high-quality quadrivalent FMD vaccines tailored to the needs of smallholder farmers in the region. With its headquarters in Istanbul and a production campus in Şanlıurfa, Dollvet brings its expertise in vaccine development and manufacturing to the competition.

The AgResults Foot and Mouth Disease Vaccine Challenge Project is an eight-year, US$17.34 million Pay-for-Results prize competition launched in February 2020. The project operates in two phases: the Development Phase, where manufacturers work to develop a regionally relevant vaccine that meets predefined criteria, and the Vaccine Distribution Cost-Share Phase, which began in October 2024. This phase features a cost-share mechanism designed to increase the distribution and adoption of quality FMD vaccines. Dollvet's entry into the project follows the registration of a quadrivalent FMD vaccine in Ethiopia that meets the project's Target Product Profile (TPP) and approval from the project's Judging Panel.

Dollvet joins Biopharma and Boehringer Ingelheim, which previously entered the competition in 2025 and 2026, respectively. According to Eyüp Sabri Göncü, Chairman of the Board at Dollvet, the company's participation in the AgResults FMD Vaccine Challenge reflects its commitment to making scientific innovation and high-quality veterinary vaccines more accessible to communities in need. Dollvet's entry is seen as an important addition to the growing range of quality FMD vaccines available in East Africa, offering buyers greater choice and improving smallholder farmers' access to vaccines.

The addition of Dollvet to the competition is expected to contribute to sustainable FMD control, stronger livestock production, and greater economic resilience for smallholder farmers. FMD remains one of the most economically damaging livestock diseases in Eastern Africa, limiting productivity, trade, and household incomes. By increasing the number of qualified manufacturers, the project aims to expand the availability and use of high-quality FMD vaccines across the region.

To mark this milestone, Dollvet will host a launch event for its FMD vaccine in Addis Ababa, Ethiopia, on November 30. According to Nina Henning, Project Manager Lead at GALVmed, Dollvet's entry is a critical step towards the project's goal of increasing the availability and use of high-quality FMD vaccines. The event will recognize Dollvet's achievement and highlight the company's commitment to protecting animal health and livelihoods.

Parasto Hamidi, AgResults Secretariat Team Lead, views Dollvet's entry as a meaningful signal that the incentives at the heart of the project are working. With a third manufacturer now competing, the project is seeing sustained industry engagement that helps build a stable, competitive market for FMD vaccines in Eastern Africa. This development brings the project closer to achieving lasting change for smallholder farmers and their animals.

The AgResults Foot and Mouth Disease Vaccine Challenge Project has made significant progress since its launch, with Dollvet's entry marking another critical step towards its goals. As the project continues to support the development and uptake of high-quality FMD vaccines, smallholder farmers in Eastern Africa can expect improved access to vaccines, protecting their livestock and livelihoods.

Key points

  • Dollvet Biyoteknoloji A.Ş. has entered the AgResults Foot and Mouth Disease Vaccine Challenge Project, expanding the availability of high-quality FMD vaccines in Eastern Africa.
  • The project aims to support the development and uptake of high-quality quadrivalent FMD vaccines tailored to the needs of smallholder farmers in the region.
  • Dollvet joins Biopharma and Boehringer Ingelheim in the competition, increasing the number of qualified manufacturers and improving access to vaccines for smallholder farmers.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.